News

Houston, Texas-based Camden Property Trust (CPT) owns, manages, develops, repositions, redevelops, acquires, and constructs multifamily apartment communities. Valued at $44.7 billion by market cap, it owns and operates 172 properties containing 58,250 apartment homes across the U.S.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and KMX perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the residential REIT industry. CPT's ability to adapt and capitalize on opportunities, and strategically reinvesting in high-growth markets maintains a competitive edge and continues to create long-term value for shareholders.

Despite its notable strength, CPT slipped 9.8% from its 52-week high of $127.69, achieved on Sep. 24. Over the past three months, CPT stock has declined 6.9%, underperforming the Dow Jones Industrials Average’s ($DOWI) 1.6% gains during the same time frame.

In the longer term, shares of CPT rose 5% over the past six months, underperforming DOWI’s 9.8% gains over the past six months. However, the stock climbed 16.5% over the past 52 weeks, outperforming DOWI’s 14.2% returns over the last year.

To confirm the bullish trend, CPT has been trading above its 200-day moving average since early May. However, the stock is trading below its 50-day moving average since early October, experiencing some fluctuations.

On Oct. 31, CPT shares closed down more than 1% after reporting its Q3 results. Its FFO of $1.71 surpassed analyst estimates of $1.68. The company’s revenue was $387.2 million, missing Wall Street forecasts of $389.2 million. For Q4, CPT expects its FFO to range from $1.68 to $1.72. The company expects full-year FFO in the range of $6.79 to $6.83.

CPT’s rival, Essex Property Trust, Inc. (ESS) lagged behind the stock with a 4% uptick over the past six months and 14.1% gains over the past 52 weeks.

Wall Street analysts are moderately bullish on CPT’s prospects. The stock has a consensus “Moderate Buy” rating from the 26 analysts covering it, and the mean price target of $127.43 suggests a potential upside of 10.6% from current price levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. More news from Barchart

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.